These guidelines replace the last publication on treatment of aspergillosis published in the year 2000.
Aspergillus species have emerged as important causes of morbidity and mortality in immunocompromised patients. Invasive aspergillosis currently constitutes the most common cause of infectious pneumonic mortality in patients undergoing
HSCT and is an important cause of opportunistic respiratory and disseminated infection in other immunocompromised patients.
Furthermore, Aspergillus species also produce a wide range of chronic, saprophytic, and allergic conditions. Although other forms of aspergillosis, such as ABPA, allergic sinusitis, and saprophytic infection, are also causes of morbidity, they are seldom life-threatening.
This document reviews guidelines for management of the 3 major forms of aspergillosis: invasive aspergillosis, chronic (and saprophytic)forms of aspergillosis, and allergic forms of aspergillosis (ABPA).
Given the public health importance of invasive aspergillosis,emphasis is placed on the diagnosis, treatment,and prevention of the different forms of invasive aspergillosis,including invasive pulmonary aspergillosis,sinus aspergillosis, disseminated aspergillosis, and several types of single-organ invasive aspergillosis.